{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:30:31Z","timestamp":1790742631339,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain, Behavior, and Immunity"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.bbi.2014.12.005","type":"journal-article","created":{"date-parts":[[2014,12,24]],"date-time":"2014-12-24T00:46:43Z","timestamp":1419382003000},"page":"28-35","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Total and differential white blood cell counts, high-sensitivity C-reactive protein, and cardiovascular risk in non-affective psychoses"],"prefix":"10.1016","volume":"45","author":[{"given":"Brian J.","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prianka","family":"Kandhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark Hyman","family":"Rapaport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Mellor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbi.2014.12.005_b0005","doi-asserted-by":"crossref","first-page":"267","DOI":"10.4088\/JCP.v65n0219","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes","volume":"65","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.bbi.2014.12.005_b0010","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1192\/bjp.171.6.502","article-title":"Excess mortality of schizophrenia. A meta-analysis","volume":"171","author":"Brown","year":"1997","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.bbi.2014.12.005_b0015","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1253\/circj.68.297","article-title":"Association of high sensitivity C-reactive protein with coronary heart disease prediction, but not with carotid atherosclerosis, in patients with hypertension","volume":"68","author":"Choi","year":"2004","journal-title":"Circ. J."},{"key":"10.1016\/j.bbi.2014.12.005_b0020","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0195-668X(03)00114-3","article-title":"Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project","volume":"24","author":"Conroy","year":"2003","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.bbi.2014.12.005_b0025","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","article-title":"General cardiovascular risk profile for use in primary care: the Framingham heart study","volume":"117","author":"D\u2019Agostino","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.bbi.2014.12.005_b0030","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s11883-010-0098-3","article-title":"Role of C-reactive protein in contributing to increased cardiovascular risk in metabolic syndrome","volume":"12","author":"Devaraj","year":"2010","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.bbi.2014.12.005_b0035","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(09)61717-7","article-title":"C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis","volume":"375","author":"Kaptoge","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.bbi.2014.12.005_b0040","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.schres.2010.02.1028","article-title":"Higher white blood cell counts are associated with an increased risk for metabolic syndrome and more severe psychopathology in non-diabetic patients with schizophrenia","volume":"118","author":"Fan","year":"2010","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbi.2014.12.005_b0045","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/0010-440X(94)90273-9","article-title":"Best-estimate versus structured interview-based diagnosis in first-admission psychosis","volume":"35","author":"Fennig","year":"1994","journal-title":"Compr. Psychiatry"},{"key":"10.1016\/j.bbi.2014.12.005_b0050","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.1360-0443.2003.00313.x","article-title":"An evaluation of the Dartmouth assessment of lifestyle inventory and the leeds dependence questionnaire for use among detained psychiatric inpatients","volume":"98","author":"Ford","year":"2003","journal-title":"Addiction"},{"key":"10.1016\/j.bbi.2014.12.005_b0055","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.amjmed.2006.02.031","article-title":"Metabolic syndrome and risk of cardiovascular disease: a meta-analysis","volume":"119","author":"Galassi","year":"2006","journal-title":"Am. J. Med."},{"key":"10.1016\/j.bbi.2014.12.005_b0060","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.schres.2005.08.010","article-title":"A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls","volume":"80","author":"Goff","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbi.2014.12.005_b0065","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"Diagnosis and management of the metabolic syndrome: an American Heart Association\/National Heart, Lung, and Blood Institute Scientific Statement","volume":"112","author":"Grundy","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.bbi.2014.12.005_b0070","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1192\/bjp.173.1.11","article-title":"Excess mortality of mental disorder","volume":"173","author":"Harris","year":"1998","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.bbi.2014.12.005_b0075","series-title":"Social Class and Mental Illness","first-page":"387","author":"Hollingshead","year":"1958"},{"issue":"8","key":"10.1016\/j.bbi.2014.12.005_b9000","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1176\/appi.ajp.2009.09060908","article-title":"Using bioinformatic tools","volume":"166","author":"Hsu","year":"2009","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bbi.2014.12.005_b0080","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.schres.2010.10.029","article-title":"Increased Framingham 10-year risk of coronary heart disease in middle-aged and older patients with psychotic symptoms","volume":"125","author":"Jin","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbi.2014.12.005_b0085","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/j.amjmed.2005.06.057","article-title":"What does minor elevation of C-reactive protein signify?","volume":"119","author":"Kushner","year":"2006","journal-title":"Am. J. Med."},{"key":"10.1016\/j.bbi.2014.12.005_b0090","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1001\/archinte.161.22.2685","article-title":"Total cholesterol\/HDL cholesterol ratio vs LDL cholesterol\/HDL cholesterol ratio as indices of ischemic heart disease risk in men: the Quebec cardiovascular study","volume":"161","author":"Lemieux","year":"2001","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.bbi.2014.12.005_b0095","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s004060070005","article-title":"The genetic epidemiology of schizophrenia and of schizophrenia spectrum disorders","volume":"250","author":"Lichtermann","year":"2000","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.bbi.2014.12.005_b0100","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/j.jacc.2004.07.056","article-title":"Leukocyte count and coronary heart disease. Implications for risk assessment","volume":"44","author":"Madjid","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.bbi.2014.12.005_b0105","first-page":"534","article-title":"Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study","volume":"183","author":"McCreadie","year":"2003","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.bbi.2014.12.005_b0110","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.schres.2005.07.014","article-title":"Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III","volume":"80m","author":"McEvoy","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbi.2014.12.005_b0115","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1176\/ps.2006.57.10.1482","article-title":"Mortality and medical comorbidity among patients with serious mental illness","volume":"57","author":"Miller","year":"2006","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.bbi.2014.12.005_b0120","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","article-title":"Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects","volume":"70","author":"Miller","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bbi.2014.12.005_b0125","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.biopsych.2012.09.007","article-title":"Meta-analysis of lymphocytes in schizophrenia: clinical status and antipsychotic effects","volume":"73","author":"Miller","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bbi.2014.12.005_b0130","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.bbi.2012.08.016","article-title":"Total and differential white blood cell counts, high-sensitivity C-reactive protein, and the metabolic syndrome in non-affective psychoses","volume":"31","author":"Miller","year":"2013","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bbi.2014.12.005_b0135","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3371\/CSRP.MICU.020813","article-title":"C-reactive protein in schizophrenia: a review and meta-analysis","volume":"7","author":"Miller","year":"2014","journal-title":"Clin. Schizophr. Relat. Psychoses"},{"key":"10.1016\/j.bbi.2014.12.005_b0140","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1017\/S003329171100105X","article-title":"Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices","volume":"42","author":"Mitchell","year":"2012","journal-title":"Psychol. Med."},{"issue":"2","key":"10.1016\/j.bbi.2014.12.005_b9005","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/schbul\/sbr148","article-title":"Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders\u2013a systematic review and meta-analysis","volume":"39","author":"Mitchell","year":"2013","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.bbi.2014.12.005_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.schres.2014.05.024","article-title":"The relationship between serum brain-derived neurotrophic factor (BDNF) and cardiometabolic indices in schizophrenia","author":"Nurjono","year":"2014","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbi.2014.12.005_b0150","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.arcmed.2006.11.006","article-title":"Relationship between white blood cell count and Framingham risk score in asymptomatic men","volume":"38","author":"Orakzai","year":"2007","journal-title":"Arch. Med. Res."},{"key":"10.1016\/j.bbi.2014.12.005_b0155","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.amjcard.2009.12.045","article-title":"Relation between C-reactive protein, homocysteine levels, fibrinogen, and lipoprotein levels and leukocyte and platelet counts, and 10-year risk for cardiovascular disease among healthy adults in the USA","volume":"105","author":"Park","year":"2010","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.bbi.2014.12.005_b0160","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.psym.2012.03.001","article-title":"Obese schizophrenia spectrum patients have significantly higher 10-year general cardiovascular risk and vascular ages than obese individuals without severe mental illness","volume":"54","author":"Ratliff","year":"2013","journal-title":"Psychosomatics"},{"key":"10.1016\/j.bbi.2014.12.005_b0165","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.amjcard.2011.09.049","article-title":"White blood cell count and risk of incident atrial fibrillation (from the Framingham heart study)","volume":"109","author":"Rienstra","year":"2012","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.bbi.2014.12.005_b0170","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1001\/archpsyc.64.10.1123","article-title":"A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?","volume":"64","author":"Saha","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.bbi.2014.12.005_b0175","first-page":"801","article-title":"Metabolic syndrome and cardiovascular risk among patients with schizophrenia receiving antipsychotics in Malaysia","volume":"53","author":"Said","year":"2012","journal-title":"Singapore Med. J."},{"key":"10.1016\/j.bbi.2014.12.005_b0180","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.eurpsy.2011.07.003","article-title":"C-reactive protein as a marker of cardiovascular disease in patients with a schizophrenia spectrum disorder treated in routine medical practice","volume":"28","author":"Sicras-Mainar","year":"2013","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.bbi.2014.12.005_b0185","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1365-2796.2006.01735.x","article-title":"Haemorheological, platelet and endothelial indices in relation to global measures of cardiovascular risk in hypertensive patients: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial","volume":"261","author":"Spencer","year":"2007","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.bbi.2014.12.005_b0190","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1176\/appi.ajp.2013.12101339","article-title":"Clinical phenotypes of psychosis in the bipolar-schizophrenia network on intermediate phenotypes (B-SNIP)","volume":"170","author":"Tamminga","year":"2013","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bbi.2014.12.005_b0195","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.schres.2013.03.023","article-title":"Increased Framingham 10-year CVD risk in Chinese patients with schizophrenia","volume":"147","author":"Tay","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbi.2014.12.005_b0200","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2147\/VHRM.S2240","article-title":"Prediction of calculated future cardiovascular disease by monocyte count in an asymptomatic population","volume":"4","author":"Waterhouse","year":"2008","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.bbi.2014.12.005_b0205","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.ehj.2004.05.002","article-title":"Associations between differential leucocyte count and incident coronary heart disease: 1764 incident cases from seven prospective studies of 30,374 individuals","volume":"25","author":"Wheeler","year":"2004","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.bbi.2014.12.005_b0210","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1161\/01.CIR.97.18.1837","article-title":"Prediction of coronary heart disease using risk factor categories","volume":"97","author":"Wilson","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.bbi.2014.12.005_b0215","doi-asserted-by":"crossref","first-page":"663","DOI":"10.4088\/JCP.v64n0607","article-title":"Chlorpromazine equivalent doses for the newer atypical antipsychotics","volume":"64","author":"Woods","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.bbi.2014.12.005_b0220","unstructured":"Woods SW, 2011. Chlorpromazine Equivalent Doses for Atypical Antipsychotics: An Update 2003-2010, <http:\/\/ scottwilliamwoods.com\/equivalencesupdate.php>."},{"key":"10.1016\/j.bbi.2014.12.005_b0225","first-page":"314","article-title":"The prevalence of metabolic syndrome and Framingham cardiovascular risk scores in adult inpatients taking antipsychotics \u2013 a retrospective medical records review","volume":"24","author":"Wysoki\u0144ski","year":"2012","journal-title":"Psychiatr. Danub."},{"key":"10.1016\/j.bbi.2014.12.005_b0230","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00406-010-0118-x","article-title":"The prevalence and clinical correlates of metabolic syndrome in patients with schizophrenia: findings from a cohort in Turkey","volume":"261","author":"Yazici","year":"2011","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."}],"container-title":["Brain, Behavior, and Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889159114005686?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889159114005686?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:41:14Z","timestamp":1760168474000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889159114005686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":48,"alternative-id":["S0889159114005686"],"URL":"https:\/\/doi.org\/10.1016\/j.bbi.2014.12.005","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725291541.793504845","asserted-by":"object"}]},"ISSN":["0889-1591"],"issn-type":[{"value":"0889-1591","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Total and differential white blood cell counts, high-sensitivity C-reactive protein, and cardiovascular risk in non-affective psychoses","name":"articletitle","label":"Article Title"},{"value":"Brain, Behavior, and Immunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbi.2014.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}